Klempner Keys in on the Pan-Tumor Potential of Seribantumab in NGR1+ Solid Tumors
Season 4, Episode 31, Feb 11, 2021, 08:13 PM
Dr. Klempner provides insight into unmet needs in NRG1 fusion–positive solid tumors, the novelty of seribantumab, and the potential clinical implications of the ongoing CRESTONE study.